Malarone Junior (Proguanil Hydrochloride, Atovaquone)

Atovaquone blocks the mitochondrial electron transport chain of the malaria parasite, halting ATP production. Proguanil is metabolised to cycloguanil, which inhibits the parasite’s dihydrofolate reductase enzyme, disrupting folate synthesis. Together they act synergistically to kill the parasite and prevent resistance.

The dose of Malarone Junior is determined by a qualified prescriber based on the child’s age, weight, indication (pre‑exposure prophylaxis or treatment) and any underlying health conditions. The prescribing professional will provide the exact regimen and duration.

Safety of Malarone Junior in pregnancy has not been established, so it should only be used if the potential benefit outweighs the risk and after consulting a healthcare provider. During breastfeeding, caution is advised because the extent of drug excretion in breast milk is unknown.

To order Malarone Junior, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Malarone Junior combines atovaquone and proguanil, offering a synergistic effect that reduces the risk of resistance compared with single‑agent therapies such as chloroquine or mefloquine. It is generally well‑tolerated and suitable for children, whereas some alternatives may have higher toxicity or limited efficacy in certain regions.

Malarone Junior should be stored at temperatures below 25 °C. Keep the tablets in their original container, protect them from moisture and direct heat, and ensure the packaging is tightly closed to maintain product stability.

Malarone Junior is taken orally as a tablet. The tablet should be swallowed whole with water, with or without food, according to the prescriber’s instructions. The regimen may differ for prophylaxis versus treatment, so follow the specific guidance provided by the healthcare professional.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, significant liver enzyme elevations indicating hepatic injury, hemolytic anemia, and severe allergic reactions (anaphylaxis). Patients should seek immediate medical attention if they notice rash, jaundice, dark urine, or breathing difficulties.

Malarone Junior should not be used by individuals with a known hypersensitivity to atovaquone, proguanil or any component of the formulation. It is also contraindicated in patients with severe renal or hepatic impairment unless specifically advised by a physician, and it should be avoided in those taking contraindicated interacting medicines.